Study of Effect of High-Flux Versus Low-Flux Dialysis Membranes on Parathyroid Hormone

Ahmed Rabie El Arbagy¹, Mahmoud Abd El Aziz Koura¹, Abd El Samad Sobhy Abou El Nasr² and Hany Said Elbarbary^1,

¹Departments of Internal Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt

²Internal Medicine Department, Benha teaching hospital, Qalyobia, Egypt

Cite this paper

Ahmed Rabie El Arbagy, Mahmoud Abd El Aziz Koura, Abd El Samad Sobhy Abou El Nasr and Hany Said Elbarbary. Study of Effect of High-Flux Versus Low-Flux Dialysis Membranes on Parathyroid Hormone. American Journal of Clinical Medicine Research. 2014; 2(1):36-42. doi: 10.12691/AJCMR-2-1-9

Abstract

Objective: Investigate the influence of permeability of low-flux versus high-flux dialysis membranes on intact PTH during hemodialysis. Background: Hyperparathyroidism is a common finding in patients with renal insufficiency and parathyroid hormone (PTH) is considered a uremic toxin responsible for many of the abnormalities of the uremic state and bone disease. Materials and Methods: Forty adult patients on regular hemodialysis were enrolled in a prospective study. Low-flux polysulfone membranes were used for at least 6 months and then the patients were switched to use high-flux polysulfone membranes for 1 month. Serum electrolytes and intact PTH before and after dialysis were compared before and after changes in dialysis membrane. Results: At the end of the 1-month use of high-flux filters, predialysis intact PTH level (415.96 ± 226.72 ng/dL) showed a significant decline (P < 0.05) compared to the predialysis intact PTH (312.28 ± 191.98 ng/dL) with low-flux membranes. Intact PTH level correlated negatively with serum calcium and positively with serum phosphorus levels only in the predialysis samples with the use of low-flux but not high-flux filters. Conclusion: High-flux dialysis membranes are more efficient in removal of intact PTH, one of the middle-sized uremic toxins, than low-flux membranes.

Keywords

Parathyroid hormone, ESRD, hemodialysis membrane

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Valder rabano F, Jofre R, Lopez-Gomez JM. Quality of life in end-stage renal disease patients. Am J Kidney Dis. 2001; 38: 443-64.
[2]	Unruh M, Benz R, Greene T, et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int. 2004; 66: 355-66.
[3]	Boure T, Vanholder R. Which dialyser membrane to choose? Nephrol Dial Transplant. 2004; 19: 293-6.
[4]	Vanholder RC, Glorieux GL, De Smet RV. Back to the future: middle molecules, high flux membranes, and optimal dialysis. Hemodial Int. 2003; 7: 52-7.
[5]	Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J. A bench to bedside view of uremic toxins. J Am Soc Nephrol. 2008; 19: 863-70.
[6]	De Francisco AL, Cobo MA, Setien MA, et al. Effect of serum phosphate on parathyroid hormone secretion during hemodialysis. Kidney Int. 1998; 54: 2140-5.
[7]	De Francisco AL, Amado JA, Prieto M, et al. Dialysis membranes and PTH changes during hemodialysis in patients with secondary hyperparathyroidism. Nephron.1994; 66: 442-6.
[8]	Morton AR, Hercz G, Coburn JW. Control of hyperphosphatemia in chronic renal failure. Semin Dial.1990; 3: 219-23.
[9]	Farrell CE. (1984): Electrolytes. In clinical chemistry theory. Analysis and correlation. The C.V. Mosby Company. Kaplan L.A., Pesce. A.J (Ed), 55, P 1054.
[10]	Fraser, Jones G, Kook SH, et al. (1987): Calcium and phosphate metabolism. In: NWTietz, (ed), Fundanintal of clinical chemistry. WB Saunders Company, Philadelphia, 3rd Edition, P 705-728.
[11]	Burtis CA and Ashwood ER. (1986): Tietz Text book of clinical chemistry, W.B. Saunders, 589.
[12]	Balducci A, Coen G, Manni M, et al. In vivo assessment of intact parathyroid hormone adsorption by different dialysis membranes during hemodialysis, Artif Organs.2004; 28 (12): 1067-75.
[13]	Makar SH, Sawiries HK, Farid TM, et al. (2010): Effect of high flux versus low flux dialysis membranes on parathyroid hormone. IJKD 4: 327-32.
[14]	Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003; 63: 1934-43.
[15]	Krieter DH, Canaud B. High permeability of dialysis membranes: what is the limit of albumin loss? Nephrol Dial Transplant. 2003; 18: 651-4.
[16]	Lindsay RM, Spanner E. A hypothesis: the protein catabolic rate is dependent upon the type and amount of treatment in dialyzed uremic patients. Am J Kidney Dis. 1989; 13: 382-9.
[17]	Marcus RG, Cohl E, Uribarri J. Middle molecule clearance does not influence protein intake in hemodialysis patients. Am J Kidney Dis. 1998; 31: 491-4.
[18]	Bergstrom J. Mechanisms of uremic suppression of appetite. J Ren Nutr. 1999; 9: 129-32.
[19]	Ayli M, Ayli D, Azak E, et al (2005): the effects of high-Flux Hemodialysis on dialysis-Associated Amyloidosis, Renal Failure; 27 (1): 31-34.
[20]	Li Y, Wang Y, Lv J, et al. (2013): Clinical outcomes for maintenance hemodialysis patients using a high-flux (FX60) dialyzer. Ren Fail. 2013 Oct; 35 (9): 1240-5.
[21]	Velasquez MT, Albertini B, Lew SQ, et al. (1998): Equal levels of blood pressure control in ESRD patients receiving high-efficiency hemodialysis and conventional hemodialysis, American Journal of Kidney Diseases; 31 (4): 618-623.
[22]	Takenaka T, Kobayashi K and Suzuki H. (2001): Warning of high-flux hemodialysis, Ren Fail; 23 (6): 819-25.
[23]	Locatelli F, Andrull S, Pecchini F, et al. (2000): Effect of high flux dialysis on the anaemia of haemodialysis patients, Nephrol, Dial, Transplant, 15, 1399-1409.
[24]	Schneider A, Drechsler C, Krane V, et al. (2012): The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD: Results of the MINOXIS Study, Clinical Journal of the American Society of Nephrology, Avilable at: http://www.mdlinx.com/ nephrology/news, last update on Januwary17, 2012. Accessed on Febrowary 12, 2012.
[25]	Locatelli F, Vecchio LD, Andrulli S, et al. (2001): Dialysis: its role in optimizing recombinant erythropoietin treatment. Nephrol Dial Transplant 16 (Supp 7): 29-35.
[26]	Drueke TB and Eckardt K. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant.2002; 17 (Supp 5): 28-31.
[27]	Urena P, Eckardt KU, Sarfati E, et al. Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: effect of parathyroidectomy. Nephron.1991; 59; 384-393.
[28]	Foulks CJ, Mills GM and Wright LF. Parathyroid hormoe and anaemia-an erythrocyte osmotic fragility study in primary and secondary hyperparathyroidism. Postgrad Med J.1989; 65: 136-139.